APA (7th ed.) Citation

C, P., J, C., M, C., H, W., & H, M. (2026). C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma. Journal of hepatocellular carcinoma, 13, 587037. https://doi.org/10.2147/JHC.S587037

Chicago Style (17th ed.) Citation

C, Pang, Chen J, Chu M, Wang H, and Miao H. "C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma." Journal of Hepatocellular Carcinoma 13 (2026): 587037. https://doi.org/10.2147/JHC.S587037.

MLA (9th ed.) Citation

C, Pang, et al. "C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma." Journal of Hepatocellular Carcinoma, vol. 13, 2026, p. 587037, https://doi.org/10.2147/JHC.S587037.